BioGaia AB (publ) (BIOGY) Stock Price & Analysis
BioGaia AB (publ) (BIOGY) — price $12.45 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.26B.
Educational signal · not a buy or sell recommendation · How to read this
BioGaia AB (publ) · BIOGY
BioGaia AB (publ) is a Swedish healthcare company specializing in the development, manufacture, and sale of probiotic products. Their offerings target gut, oral, and immune health, with a global presence across multiple continents.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $12.45 | |
| Change on the day | 0.00% | |
| 52-week range | $9.64 – $12.45 | |
| Market capitalisation | $1.26B | — |
| Price / earnings (trailing) | 32.38 | |
| Shares traded on the day | 1 |
Price & events
Other perspectives
Council score for BioGaia AB (publ) (BIOGY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 27, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BioGaia AB (publ) (BIOGY), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BioGaia AB (publ) (BIOGY) is the company analyzed here. It employs 242 people and is led by Theresa Agnew. In Q3 FY2026 it reported revenue of kr400M and net income of kr110M. The market values it at $1.26B.
What do the latest results show for BioGaia AB (publ) (BIOGY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of kr400M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | kr400M | kr110M | kr1.09 (diluted) |
| Q2 FY2026 | kr441M | kr103M | kr1.02 (diluted) |
| Q1 FY2026 | kr373M | kr79M | kr0.78 (diluted) |
| Q4 FY2025 | kr441M | kr99M | kr0.98 (diluted) |
What are the financial strengths and risks for BioGaia AB (publ) (BIOGY)?
Short answer · as of
The distress and quality screens read Altman Z 35.80 · Piotroski F 5. Trailing ratios: ROE 31.1% · ROA 27.0% · current ratio 5.14 · earnings yield 3.1% · free-cash-flow yield 2.1%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BIOGY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BIOGY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BioGaia AB (publ) (BIOGY)?
Investor Questions: BIOGY Stock
These answers are editorial: 1 of these 8 answers is drawn from the BIOGY research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is BIOGY a good stock to buy?
Stock Expert AI does not rate BIOGY buy, sell or hold. BioGaia AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BIOGY stock price today?
The last price recorded for BioGaia AB (publ) (BIOGY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does BioGaia AB (publ) do?
BioGaia AB (publ) is a healthcare company specializing in the development, manufacture, and sale of probiotic products. Its core focus is on improving gut, oral, and immune health through probiotic solutions. The company operates through three segments: Pediatrics, Adult Health, and Other.
What are the key factors to evaluate for BIOGY?
Evaluate BIOGY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. This approach can drive premium pricing and increase customer loyalty. Not financial advice.
How frequently does BIOGY data refresh on this page?
BIOGY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BIOGY's recent stock price performance?
BioGaia AB (publ) (BIOGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary probiotic strains with clinical backing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIOGY overvalued or undervalued right now?
The trailing P/E of BioGaia AB (publ) (BIOGY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BIOGY before investing?
Before investing in BioGaia AB (publ) (BIOGY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com